Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Elizabeth L. Lockerman"'
Autor:
Lecia V. Sequist, Jeffrey A. Engelman, Andrew R. Allen, Alice T. Shaw, A. John Iafrate, Dora Dias-Santagata, Richard H. DiCecca, Melissa K. Parks, Hillary E. Mulvey, Angel R. Garcia, Mitch Raponi, Alona Muzikansky, Subba Digumarthy, Anuj Kalsy, Elizabeth L. Lockerman, Aaron N. Hata, Linnea Fulton, Mari Mino-Kenudson, Joel W. Neal, Heather A. Wakelee, Chris A. Karlovich, Matthew J. Niederst, Zofia Piotrowska
Supplementary Figure S1. CONSORT diagram. Supplementary Figure S2. Histologic analysis of the pre-rociletinib biopsy from patient 12 (H&E 400x, left panel) demonstrates characteristic adenocarcinoma with an open chromatin pattern, ample cytoplasm and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::437ca3efda6e4b1a14798fe61a036ad6
https://doi.org/10.1158/2159-8290.22530498.v1
https://doi.org/10.1158/2159-8290.22530498.v1
Autor:
Jeffrey A. Engelman, Alice T. Shaw, Jennifer L. Harris, Makoto Nishio, Naoya Fujita, Elizabeth L. Lockerman, Sidra Mahmood, Peter McNamara, Su Hua, Xiuying Sun, Frank Sun, Shailaja Kasibhatla, Jie Li, AnneMarie C. Pferdekamper, Sungjoon Kim, Noriko Yanagitani, Mark M. Awad, Pierre-Yves Michellys, Adam S. Crystal, Justin F. Gainor, Christian C. Lee, Ryohei Katayama, Nanxin Li, Luc Friboulet
PDF file 70K, This table contains the IC50 values of in vitro cell survival assay for crizotinib or ceritinib in engineered EML4-ALK mutant Ba/F3 cells corresponding to Fig 4A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbbad5b9475ebf740303ecca033f51a2
https://doi.org/10.1158/2159-8290.22530507.v1
https://doi.org/10.1158/2159-8290.22530507.v1
Autor:
Ryan B. Corcoran, Levi A. Garraway, Jeffrey A. Engelman, A. John Iafrate, Dora Dias-Santagata, Gad Getz, Mari Mino-Kenudson, Tiffany G. Huynh, Niall J. Lennon, Lisa M. Green, Kristin Anderka, Samira Bahl, Joseph M. Gurski, Anuj Kalsy, Elizabeth L. Lockerman, Craig H. Mermel, Kerry D. Lynch, Koki Nishimura, Jason T. Godfrey, Jason E. Faris, Eunice L. Kwak, Nikhil Wagle, Eliezer M. Van Allen, Erin M. Sennott, Leanne G. Ahronian
Supplementary Figure S5. Role of ARAF Q489L and MEK F53L in resistance.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::159b92665530fed33babe57bbb3fb25d
https://doi.org/10.1158/2159-8290.22530041.v1
https://doi.org/10.1158/2159-8290.22530041.v1
Autor:
Ryan B. Corcoran, Levi A. Garraway, Jeffrey A. Engelman, A. John Iafrate, Dora Dias-Santagata, Gad Getz, Mari Mino-Kenudson, Tiffany G. Huynh, Niall J. Lennon, Lisa M. Green, Kristin Anderka, Samira Bahl, Joseph M. Gurski, Anuj Kalsy, Elizabeth L. Lockerman, Craig H. Mermel, Kerry D. Lynch, Koki Nishimura, Jason T. Godfrey, Jason E. Faris, Eunice L. Kwak, Nikhil Wagle, Eliezer M. Van Allen, Erin M. Sennott, Leanne G. Ahronian
Supplementary Table S1. Patient characteristics and MAPK pathway reactivating resistance mechanisms of BRAF-mutant CRC patients with clinical acquired resistance to RAF/EGFR or RAF/MEK inhibitor combinations.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68672d23e9c3704897ff3623acae1192
https://doi.org/10.1158/2159-8290.22530038
https://doi.org/10.1158/2159-8290.22530038
Autor:
Jeffrey A. Engelman, Alice T. Shaw, Jennifer L. Harris, Makoto Nishio, Naoya Fujita, Elizabeth L. Lockerman, Sidra Mahmood, Peter McNamara, Su Hua, Xiuying Sun, Frank Sun, Shailaja Kasibhatla, Jie Li, AnneMarie C. Pferdekamper, Sungjoon Kim, Noriko Yanagitani, Mark M. Awad, Pierre-Yves Michellys, Adam S. Crystal, Justin F. Gainor, Christian C. Lee, Ryohei Katayama, Nanxin Li, Luc Friboulet
PDF file 135K, Figure S1 contains data about Ceritinib specificity and potency on crizotinib na?ve EML4-ALK wild-type cells. Figure S2 contains the Cell survival curves of H3122 CR1, MGH021-4 and MGH045 cells following treatment with Crizotinib or ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ef66a8df7dccfca8800c87972d78cb6
https://doi.org/10.1158/2159-8290.22530510
https://doi.org/10.1158/2159-8290.22530510
Autor:
Jeffrey A. Engelman, Alice T. Shaw, Jennifer L. Harris, Makoto Nishio, Naoya Fujita, Elizabeth L. Lockerman, Sidra Mahmood, Peter McNamara, Su Hua, Xiuying Sun, Frank Sun, Shailaja Kasibhatla, Jie Li, AnneMarie C. Pferdekamper, Sungjoon Kim, Noriko Yanagitani, Mark M. Awad, Pierre-Yves Michellys, Adam S. Crystal, Justin F. Gainor, Christian C. Lee, Ryohei Katayama, Nanxin Li, Luc Friboulet
PDF file 100K, Legends for the supplementary figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0ea846b0c38725c52287939c9514120
https://doi.org/10.1158/2159-8290.22530513
https://doi.org/10.1158/2159-8290.22530513
Autor:
Lecia V. Sequist, Jeffrey A. Engelman, Andrew R. Allen, Alice T. Shaw, A. John Iafrate, Dora Dias-Santagata, Richard H. DiCecca, Melissa K. Parks, Hillary E. Mulvey, Angel R. Garcia, Mitch Raponi, Alona Muzikansky, Subba Digumarthy, Anuj Kalsy, Elizabeth L. Lockerman, Aaron N. Hata, Linnea Fulton, Mari Mino-Kenudson, Joel W. Neal, Heather A. Wakelee, Chris A. Karlovich, Matthew J. Niederst, Zofia Piotrowska
Supplementary Figure Legends. Supplementary Table S1. Patient characteristics. Supplementary Table S2. Tissue genotyping analyses. Supplementary Table S3. Allelic Fraction of T790M and maximum reduction in tumor volume in response to rociletinib.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03fcd94a89f7fb896d66c6fc6bab2516
https://doi.org/10.1158/2159-8290.22530501
https://doi.org/10.1158/2159-8290.22530501
Autor:
Jeffrey A. Engelman, Lecia V. Sequist, Zofia Piotrowska, Angel R. Garcia, Elizabeth L. Lockerman, Hillary E. Mulvey, Haichuan Hu, Matthew J. Niederst
Supplementary Figure 1 Legend. Describing the qPCR assay and variant allele frequency data that are included in the figure.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e18167c22ba9c0611b588fce9c6740d
https://doi.org/10.1158/1078-0432.22457907
https://doi.org/10.1158/1078-0432.22457907
Autor:
Anthony C. Faber, Jeffrey A. Engelman, Hiromichi Ebi, Bradley Bernstein, Lecia V. Sequist, Mikhail Dozmorov, Shirley M. Taylor, Sinem E. Sahingur, Zofia Piotrowska, Brad E. Windle, Tara J. Nulton, Maria Gomez-Caraballo, Hannah L. Archibald, Shawn Gillepsie, Angel Garcia, Elizabeth L. Lockerman, Neha U. Patel, Mark T. Hughes, Daniel A.R. Heisey, Yotam Drier, Hillary E. Mulvey, Haichuan Hu, Mark A. Hicks, Konstantinos V. Floros, Jungoh Ham, Hidenori Kitai, Aaron N. Hata, Timothy L. Lochmann, Matthew J. Niederst, Kyung-A Song
Supplemental legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cdf55fda2d52240554b29e627d0a09c
https://doi.org/10.1158/1078-0432.22462238
https://doi.org/10.1158/1078-0432.22462238
Autor:
Jeffrey A. Engelman, Lecia V. Sequist, Zofia Piotrowska, Angel R. Garcia, Elizabeth L. Lockerman, Hillary E. Mulvey, Haichuan Hu, Matthew J. Niederst
Purpose: A secondary EGFR mutation, T790M, is the most common resistance mechanism in EGFR-mutant adenocarcinomas that have progressed on erlotinib. Third-generation EGFR inhibitors capable of inhibiting mutant EGFR with T790M produce responses in ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59e3f5cd6fe326d292cde875d4764bd7
https://doi.org/10.1158/1078-0432.c.6523746.v1
https://doi.org/10.1158/1078-0432.c.6523746.v1